Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Non-cash Items (2017 - 2025)

Historic Non-cash Items for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $12.4 million.

  • Aclaris Therapeutics' Non-cash Items rose 782.61% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year increase of 782.61%. This contributed to the annual value of $10.0 million for FY2024, which is 7132857.14% up from last year.
  • Per Aclaris Therapeutics' latest filing, its Non-cash Items stood at $12.4 million for Q3 2025, which was up 782.61% from $14.0 million recorded in Q2 2025.
  • Aclaris Therapeutics' Non-cash Items' 5-year high stood at $40.3 million during Q1 2023, with a 5-year trough of $14000.0 in Q4 2023.
  • In the last 5 years, Aclaris Therapeutics' Non-cash Items had a median value of $16.6 million in 2024 and averaged $19.8 million.
  • As far as peak fluctuations go, Aclaris Therapeutics' Non-cash Items crashed by 9990.84% in 2023, and later soared by 7132857.14% in 2024.
  • Aclaris Therapeutics' Non-cash Items (Quarter) stood at $13.7 million in 2021, then increased by 11.51% to $15.3 million in 2022, then tumbled by 99.91% to $14000.0 in 2023, then skyrocketed by 71328.57% to $10.0 million in 2024, then grew by 24.0% to $12.4 million in 2025.
  • Its Non-cash Items stands at $12.4 million for Q3 2025, versus $14.0 million for Q2 2025 and $14.9 million for Q1 2025.